Latest Strategic Acquisitions News

Netwealth Group Limited reported a standout FY2025 with net profit rising nearly 40% and funds under administration climbing 28%, underpinning a 37.5% increase in dividends. Strategic fintech acquisitions and robust governance enhancements position the company for sustained growth.

Qube Holdings Limited reported robust FY25 underlying revenue growth of 27%, driven by strong performances in its Logistics & Infrastructure and Ports & Bulk divisions, while declaring a 71% increase in full-year dividends. Despite challenges including industrial action and weather disruptions, Qube expects continued earnings growth in FY26 supported by strategic acquisitions and operational resilience.

Ridley Corporation reported solid FY25 results with EBITDA up 8.6% to $97.8 million and NPAT rising 8.7% to $43.3 million, underpinned by strategic acquisitions and disciplined capital management.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion driven by volume growth and strategic acquisitions, while profits declined amid inflationary pressures. The company declared a final dividend of 6.5 cents per share and maintains zero net debt.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Redox Ltd reported a robust 9.4% increase in revenue for FY25, supported by strong volume growth and three strategic acquisitions, despite margin compression and a challenging macroeconomic backdrop.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

Charter Hall Group reported a robust FY25 with a 7.3% rise in operating earnings per security and a surge in funds under management to $84.3 billion. The group’s strategic equity inflows and development pipeline expansion signal strong momentum heading into FY26.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion amid challenging global conditions, while profit after tax declined 14.6% to $77.1 million due to margin normalization and rising costs. The company completed three strategic acquisitions and declared a fully franked dividend of 12.5 cents per share.

Peter Warren Automotive Holdings reported a modest revenue increase but a sharp profit decline in FY25, unveiling a new CEO and a refreshed growth strategy to tackle industry challenges.

IPH Limited reported a solid 16.5% revenue increase to $710.3 million for FY25, driven by strategic acquisitions in Canada and strong organic growth in Asia and ANZ. Despite ongoing delays at the Canadian Intellectual Property Office, the company achieved higher earnings and dividends, setting the stage for further operational efficiencies and technology investments.